**Enterovirus and parechovirus meningitis in infants younger than 90 days old in the United Kingdom and Republic of Ireland: a British Paediatric Surveillance Unit study**

Seilesh Kadambari 1,2, Serena Braccio 1, Sonia Ribeiro3, David J Allen 4, Richard Pebody 5, David Brown 4, Robert Cunney6, Mike Sharland 1, Shamez Ladhani1,3

1 Paediatric Infectious Diseases Research Group, St George’s University of London, Cranmer Terrace, London SW17 0RE

2 Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK

Email: seilesh.kadambari@paediatrics.ox.ac.uk

Phone: +44 1865 226 953

3Immunisation, hepatitis and blood safety department, Public Health England, Colindale, London

4 Virology Reference Department, Public Health England, Colindale, London

5 Influenza and other Respiratory Viruses Section, Public Health England, Colindale, London

6 Department of microbiology, Temple Street Children’s University Hospital, Temple Street

Dublin

Category: Original article

Keywords: Enterovirus, Parechovirus, Meningitis, Infants, Surveillance

Running title: Enterovirus and parechovirus meningitis

**Abstract**

**Objectives**

This study aimed to prospectively collect detailed clinical information for all enterovirus (EV) and human parechovirus (HPeV) meningitis cases in infants aged <90 days in the United Kingdom and Ireland.

**Participants, design and setting:**

Prospective, active national surveillance during July 2014/15 through the British Paediatric Surveillance Unit. Reporting paediatricians completed questionnaires requesting information on clinical presentation, investigations, management and outcomes at hospital discharge and after 12 months.

**Main Outcome Measures:**

To describe the clinical burden of EV and HPeV meningitis in infants aged <90 days.

**Results**

During the 13-month surveillance period, 703 cases (668 EV, 35 HPeV) were reported. The most common clinical presentations were fever (EV: 570/668 [85%]; HPeV: 28/35 [80%]), irritability (EV: 441/668 [66%]; HPeV: 23/35 [66%]) and reduced feeding (EV: 363/668 [54%]; HPeV 23/35 [66%]). Features of circulatory shock were present in 27% (182/668) of EV and 43% (15/35) of HPeV cases. Overall, 11% (76/668) of EV and 23% (8/35) of HPeV cases required intensive care support. Nearly all cases (678/703, 96%) were confirmed by cerebrospinal fluid (CSF) PCR, with 52% (309/600) having normal CSF white cell count for age. Two infants with EV meningitis died (2/668, 0.3%) and four survivors (4/666, 0.6%) had long-term complications at 12-months follow-up. Infants with HPeV meningitis survived without sequelae. 70% (189/270) had a formal hearing test, none had sensorineural hearing loss.

**Conclusion**

The incidence of laboratory-confirmed EV/HPeV meningitis in young infants is more than twice that for bacterial meningitis. Less than 1% will develop severe neurological complications or die of their infection. Further studies are required to formally assess long-term neurodevelopmental sequelae.

**Introduction**

Hospitalisation rates for childhood viral meningitis in England have increased year-on-year over the past decade, reaching 70 per 100 000 children in 2011, with the highest rates reported in infants younger than 90 days (1). This trend coincides with increasing routine use of molecular assays such as polymerase chain reaction (PCR) testing for viral infections in local hospital laboratories, which has led to a seven-fold increase in reports of laboratory-confirmed cases of viral meningo-encephalitis in the past decade (2). Enteroviruses (EV) accounted for half of nearly 10,000 reports and 92% of EV meningitis cases were reported in <3 month-olds (2). Human parechoviruses (HPeV) belong to the *Picornaviridae* family and can also cause viral meningo-encephalitis in infants, albeit less frequently than EV (3).

EV and HPeV usually cause mild, self-limiting respiratory and gastointestinal infections in children. Occasionally, however, they may be responsible for more serious illness, including meningo-encephalitis, hepatitis, myocarditis or fulminant sepsis (4). Recent outbreaks associated with long-term neurological complications have been reported in Australia, northern Europe and USA (4–7). In neonates and young infants, viral meningitis can be difficult to diagnose and differentiate from more serious invasive bacterial infections because of their non-specific clinical presentation, especially in the early stages of illness (8,9), and lack of specific laboratory markers (10). Testing for EV/HPeV by clinicians and microbiologists across hospital laboratories is also variable because of differences in local protocols and limited understanding of clinical presentations, disease progression and outcomes. Additionally, there are no approved treatments for EV/HPeV infections and no investigational therapies undergoing clinical trials in Europe, in part due to lack of robust data to support the need for effective therapeutics. The last UK publication on enterovirus epidemiology included retrospective data collected more than 20 years ago (11). We, therefore, undertook a prospective, population-based surveillance study to define the burden, clinical characteristics, investigations, management and outcomes of EV/HPeV meningitis in young infants across the UK and Republic of Ireland.

**Methods**

**Surveillance**

This study was conducted by Public Health England (PHE) and St. George’s University of London through the British Paediatric Surveillance Unit (BPSU), a unique national clinical surveillance system set up to study rare diseases (12). The BPSU functions by sending paediatric consultants across the UK and Ireland a short electronic list of rare childhood conditions every month. All paediatricians are asked to respond and report whether they have seen a case (such as EV/HPeV meningitis) or confirm that they had no cases to report. Reporting is not compulsory but strongly encouraged, with regular reminders sent by the BPSU if no response is received. Following a positive report, the reporting paediatrician completes a detailed questionnaire on the case.

The study began on 01 July 2014 and continued for 13 months. A case was defined as a hospitalised infant aged <90 days at diagnosis with laboratory-confirmed EV/HPeV meningitis with clinical features of meningitis (fever ≥ 38oC, coma, seizures, neck stiffness, apnoea, bulging fontanelle, irritability, lethargy, poor feeding)and laboratory confirmation of EV/HPeV from any site (CSF, blood, stool, throat, peri-anal swab). The Second Generation Surveillance System (SGSS), a national electronic reporting system used by NHS laboratories to notify clinically significant infections to Public Health England (PHE), was used as an alternative national data source for cases with EV/HPeV detected in the CSF in England, Wales and Northern Ireland. Additional cases identified through SGSS were followed-up in the same way as the BPSU-reported cases. Paediatricians who completed the clinical questionnaires were contacted after 12 months with a follow-up questionnaire on long-term outcomes.

**Data analysis**

Data were entered into Microsoft Access and analysed using STATA 14.0 (StataCorp, College Station, Texas). Table 1 outlines a full list of clinical definitions. Annual incidence was calculated using published live-births for each of the nations in 2014 after adjustment for the 13-month surveillance period. Data are mainly descriptive and summarised as medians with interquartile ranges or proportions, and compared using the Mann Whitney U test or the Chi squared or Fisher exact test, respectively. The binomial method was used to calculate the 95% confidence intervals (CI) for proportions.

**Ethics Approval**

The study has been approved by the London Queen Square research ethics committee (Ref: 14/LO/0229).

**Results**

During the 13-month surveillance period, 754 reports of EV/HPEV meningitis in infants aged <90 days were received and 703 (93%) fulfilled the case definition, including 668 (95%) with EV meningitis and 35 (5%) with HPeV meningitis. The number of cases peaked in summer (**Fig 1**). The annual incidence of EV meningitis was 0.79per 1,000 live-births and 0.04 per 1,000 live-births for HPeV meningitis. EV serotype information was available for 67% (448/668) of cases and included echovirus (54%, 242/448), coxsackie B5 (7%, 32/448), coxsackie B4 (6%, 28/448) and enterovirus 71 (4%, 17/448). None of the HPeV strains were typed.

The median age at diagnosis was 34 (IQR, 15 -53) days, and 58% (410/703 cases) were male. EV and HPeV cases were indistinguishable in terms of age distribution, clinical presentation and laboratory markers; none of the parameters were statistically significant (**Fig 2**). Among EV cases, fever ($\geq $38°C) was the commonest presentation (85%, 570/668), followed by irritability (66%, 441/668), reduced feeding (54%, 363/668) and lethargy (36%, 243/668). Fever was also the most common presentation in infants with HPeV meningitis (80%, 28/35) cases, followed by reduced feeding (71%, 25/35), irritability (66%, 23/35) and lethargy (51% 18/35) (**Fig 2**). On examination, the most common finding was circulatory shock in 27% (182/668) of EV and 43% (15/35) of HPeV cases, followed by respiratory distress (EV, 12% [79/668]; HPeV, 26% [9/35]) and rash (EV, 24% [163/668]; HPeV, 29% [10/35]). Of note, 17% (6/35) of infants with HPeV meningitis had abdominal distension and 11% (4/35) had a reduced Glasgow Coma Scale (<11/15) at presentation.

**Intensive care admission**

Most EV cases were admitted to the paediatric ward (78%, 522/668) or short-term assessment unit (9%, 59/668), while 11% required admission to a paediatric intensive care (PICU; 7%, 46/668) or high dependency unit (HDU; 4%, 30/668). Of the 35 HPeV cases, 23% required PICU (17%, 6/35) or HDU (6%, 2/35) admission. Almost half the infants who presented in the first week of life (42%, 29/69) required PICU admission (**Table 2**). Half (50%, 23/46) the EV meningitis cases and all six HPeV cases in ICU required intubation and ventilation for a median of 5 and 4 days, respectively. A fifth (20%, 9/46) of EV meningitis cases and all HPeV cases required inotropic support. The most common EV serotypes responsible for PICU cases included echovirus 7 (n=4) and echovirus 9 (n=4), coxsackie B4 (n=3), echovirus 11 (n=3) and enterovirus 71 (n=1).

**Diagnosis and investigation**

Nearly all reported cases (96%, 678/703) were diagnosed through detection of virus in the CSF. The virus was also identified in the stool in 10% (69/703), blood in 5% (38/703) and throat swabs in 5% (34/703). Of those with reported CSF results, half the EV (51%, 304/600) and all HPeV (100%, 29/29) meningitis cases had less than 20 white cells per mm3 in the CSF. Most cases also had a normal peripheral blood white cell counts (6-15 x109/L); EV: 85% (506/598) and HPeV: 56% (18/32). In addition, more than half the EV (56%, 360/643) and HPeV (67%, 22/33) cases had a CRP (C-reactive protein) level <10 mg/dL (**Fig 2**).

Six infants had coagulase-negative Staphylococci (CoNS) isolated from blood cultures (n=5) or CSF (n=1); all were considered to be contaminants and not treated with antibiotics.

In total, 8% (56/668) of EV and 29% (10/35) of HPeV meningitis cases had cranial ultrasound scans during admission. Relatively mild abnormalities were noted in five cases with EV meningitis (2 cases had resolving grade 1 IVH and 3 cases small choroid plexus bleeds with normal parenchyma). Overall, 3% (17/668) of EV meningitis cases had an MRI head scan during admission and eight were abnormal (white matter changes [n=3], and one case each of subdural haemorrhage, posterior fossa blood collection, acute infarct in the right corona, severe cystic encephalomalacia and mild ventricular dilatation).

**Treatment and outcomes at hospital discharge**

 A significant proportion of cases were treated with acyclovir in addition to empiric intravenous antibiotics (EV meningitis 27% 183/668; HPeV meningitis 46%, 16/35). The median duration of acyclovir treatment was 3.1. days. Three EV and one HPeV cases were also treated with intravenous immunoglobulin; the indication for administering immunoglobulin was not stated. Two infants with EV meningitis died (2/668; case fatality rate, 0.3%; 95% CI, 0.04-1.1%). Of the survivors, two had significant neurological sequelae at hospital discharge, which were still present at 12 months follow-up (Table 2). None of the infants with HPeV meningitis died and one had transaminitis at hospital discharge, which resolved spontaneously. Prematurity status, age at diagnosis and EV serotype were not associated with more severe clinical presentation or poor outcome at discharge**.**

**Follow-up at 12 months**

Follow-up questionnaires were sent to all paediatricians who had reported a case. In total, 38% (254/668) of EV and 46% (16/35) HPeV infants were reviewed by the clinical team on at least one occasion during 12 months after hospital discharge. Of these, 70% (189/270) had a formal hearing test after discharge from hospital and none of those tested had sensorineural hearing loss. At follow-up, two additional infants with EV meningitis, who were well at discharge, were identified with neurological complications by 12 months. The risk of long-term sequelae among infants with EV meningitis who were followed up was 0.6% (4/666; 95% CI, 0.2-1.5%) (Table 3).

**Discussion**

We have reported the largest prospective national study to evaluate the burden, clinical characteristics and outcomes of EV/HPeV meningitis in young infants during a period devoid of local or national outbreaks. We found some evidence of more severe disease in infants with HPeV compared to EV meningitis, with higher rates of circulatory failure, PICU admission and requirement for multi-organ support. Two of the 668 infants with EV meningitis died and four others had long-term neurodevelopmental complications at 12 months follow-up, while the small number of infants with HPeV meningitis recovered without complications

The incidence of laboratory-confirmed EV/HPeV meningitis is >2-fold higher than recent estimates for bacterial meningitis in the same age-group (0.38/1000 live births) using the same surveillance methodology (13). This incidence is also >5 times higher than group B streptococcal meningitis, currently the single most important cause of bacterial meningitis in young infants (13). Our estimates are, however, likely to be significantly under-estimated for several reasons. Infants with EV/HPeV meningitis often have normal peripheral white cell counts and CRP levels, which can reassure clinicians against further investigations. Even when lumbar puncture is performed, more than half do not exhibit CSF pleocytosis, and, therefore, may not undergo further testing for viruses (8). Many hospital laboratories only test CSF samples for viruses in the presence of CSF pleocytosis and negative bacterial cultures. As multiplex PCR-testing becomes more established, however, laboratories are increasingly testing all CSF samples routinely for viruses, especially in infants. This in part explains the rapidly increasing reports of EV/HPeV infections in England in recent years (2).

Another major consideration is that 96% of cases were diagnosed through virus detection in the CSF. Paediatricians need to be aware that some of these viruses may only be detected at a peripheral site, such as the upper respiratory tract, blood or stools; specimens from these sites should, therefore, also be routinely tested in infants with suspected meningitis (14). Rapid diagnosis will help rationalise antimicrobial use, guide additional investigations, support early hospital discharge and reassure parents about long-term outcomes (15,16).

The finding that nearly 10% of cases were diagnosed within the first week of life, without any particular association with EV/HPeV type, suggests transplacental transmission in this cohort because of the relatively short interval between birth and illness; transplacental transmission has been demonstrated in a previous prospective cohort study which identified echovirus 11  from the respiratory or gastrointestinal tract of 4 out of 7 infected neonates by three days of age and also in their mothers at term (17). The lack of CSF pleocytosis in half the cases has been reported in the literature but is not widely known among clinicians and microbiologists. In a recent, retrospective South Korean study involving 390 children with EV meningitis, 16-18% did not have CSF pleocytosis, but this proportion increased to 68-77% in neonates; young age, lower peripheral WBC count and shorter interval between illness onset and lumbar puncture were associated with the absence of CSF pleocytosis (18). Our study highlights the importance of performing lumbar punctures in unwell young infants with non-specific presentations and routinely testing for EV/HPeV in the CSF and other sites.

Viral meningitis is generally associated with good outcomes but there is a paucity of robust follow-up data for infants. We, for the first time, are able to reliably estimate the low but significant risk of serious outcomes in young infants with EV/HPeV meningitis, supporting some of the previous studies (19) (20), although others have reported no (21–23)or only mild (24) complications at follow-up. Most of these studies were conducted >20 years ago, used crude developmental assessment tools at inconsistent times after the acute illness and evaluated small numbers of infants. Notably, in our cohort, although only 38% of infants underwent audiological testing after hospital discharge, none had hearing loss, which is in keeping with another recent UK national surveillance of 106 infants with HPeV and supports current consensus that audiological follow up after hospital discharge in infants with EV and HPeV meningitis is not routinely required in infants who are otherwise well at hospital discharge (25).

HPeV represented a small proportion of our cases, partly because HPeV infections peak every two years and this study was conducted in a year of low HPeV activity (4,26,27). Additionally, many hospital laboratories still do not routinely test for HPeV, even those that routinely test for EV, although an increasing number of hospital laboratories have been adding HPeV testing to their existing multiplex PCR assays recently (28).

Several studies have reported significant long-term neurodevelopmental sequelae in infants with HPeV meningitis, especially associated with HPeV type 3 (29) (30). These studies, however, often reported a small and highly selective group of infants with very severe clinical presentations, but they do highlight the potential for this virus to cause permanent irreversible neurological damage. These results also question whether those with less severe clinical presentations might go on to develop subtle long-term complications that remain undetected.

Additional robust long-term neurodevelopmental studies with larger numbers of cases are required to provide an evidence base for management of infants with viral meningitis beyond hospital discharge.

The strength of this study lies in the prospective national surveillance that captured all cases across the UK and Ireland over a relative short time period. A limitation of our study is the low proportion of EV/HPeV strains submitted for typing to the PHE reference laboratory (31); we were, therefore, unable to assess correlations between serotype and poor outcomes, which were rare. Additionally, as there are no currently no evidence-based guidelines, clinical investigations and management as well as outpatient follow-up of infants was haphazard, with only 30% of infants reviewed after hospital discharge. It is, therefore, possible that our estimate of long-term complications may be underestimated

In conclusion, the incidence of laboratory-confirmed EV/HPeV meningitis in young infants is more than twice that for bacterial meningitis in the UK and Ireland. Around 1% of infants will develop significant complications or die of their infection. Further studies are required to determine long-term neurodevelopmental sequelae in infants who are well at hospital discharge. Clinicians should consider formal neurodevelopmental assessment in infants with persistent symptoms, and those with severe neurological presentations and/or abnormal neuroimaging findings during the acute illness.

What’s known on this subject:

* Enterovirus and human parechovirus are common causes of infant meningitis.
* The clinical burden of disease is unknown due to a lack of robust epidemiological data.
* No antiviral or vaccines are licenced in Europe or the USA to treat or prevent disease.

What this study adds:

* In UK infants, the combined incidence of EV (0.79/1,000 live-births) and HPeV (0.04/1,000 live-births) meningitis is more than double that for bacterial meningitis
* More than half the infants had absent CSF pleocytosis and low inflammatory markers.
* Less than 1% of infants developed significant complications or died of their infection.

**Funding:** none declared.

**Contributors** S.K and S.L conceptualised and designed the study, drafted the initial manuscript, and reviewed and revised the manuscript. S.B and S.R designed the data collection instruments, collected data and reviewed and revised the manuscript.

D.J.A, R.C, R.P, D.B and M.S conceptualized and designed the study, coordinated and supervised data collection, and critically reviewed the manuscript for important intellectual content.

**References**

1. Martin NG, Iro MA, Sadarangani M, Goldacre R, Pollard AJ, Goldacre MJ. Hospital admissions for viral meningitis in children in England over five decades: a population-based observational study. Lancet Infect Dis. 2016;16(11):1279–87.

2. Kadambari S, Okike I, Ribeiro S, Ramsay ME, Heath PT, Sharland M, et al. Seven-fold increase in viral meningo-encephalitis reports in England and Wales during 2004-2013. J Infect [Internet]. Elsevier Ltd; 2014 Jun 2 [cited 2014 Jul 24]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/24887614

3. Harvala H, Simmonds P. Human parechoviruses: biology, epidemiology and clinical significance. J Clin Virol [Internet]. 2009 May [cited 2014 Jul 24];45(1):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19372062

4. Vergnano S, Kadambari S, Whalley K, Menson EN, Martinez-Alier N, Cooper M, et al. Characteristics and outcomes of human parechovirus infection in infants (2008-2012). Eur J Pediatr [Internet]. 2015 Jan 10 [cited 2015 May 19]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25573462

5. Sharp J, Harrison CJ, Puckett K, Selvaraju SB, Penaranda S, Nix WA, et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J [Internet]. 2013 Mar [cited 2014 Dec 14];32(3):213–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23042051

6. Khatami A, McMullan BJ, Webber M, Stewart P, Francis S, Timmers KJ, et al. Sepsis-like disease in infants due to human parechovirus type 3 during an outbreak in Australia. Clinical Infectious Diseases. 2015. p. 228–36.

7. Wildenbeest JG, Benschop KSM, Minnaar RP, Bouma-de Jongh S, Wolthers KC, Pajkrt D. Clinical relevance of positive human parechovirus type 1 and 3 PCR in stool samples. Clin Microbiol Infect. 2014;20(10):O640–7.

8. Sadarangani M, Willis L, Kadambari S, Gormley S, Young Z, Beckley R, et al. Childhood meningitis in the conjugate vaccine era: a prospective cohort study. Arch Dis Child [Internet]. 2015;100(3):292–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25256088

9. Tebruegge M, Curtis N. Enterovirus infections in neonates. Semin Fetal Neonatal Med [Internet]. 2009 Aug [cited 2014 Mar 3];14(4):222–7. Available from: http://www.sciencedirect.com/science/article/pii/S1744165X09000237

10. Abzug MJ, Loeffelholz M, Rotbart HA. Diagnosis of neonatal enterovirus infection by polymerase chain reaction. J Pediatr [Internet]. 1995 Mar [cited 2014 Aug 27];126(3):447–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7869209

11. Maguire HC, Atkinson P, Sharland M BJ. Enterovirus infections in England and Wales: laboratory surveillance data: 1975 to 1994. Commun Dis Public Heal. 1999;(2):122–5.

12. Hall SM, Nicoll A. The British Paediatric Surveillance Unit- a pioneering method for investigating the less common disorders of childhood. Child Care Health Dev [Internet]. 1998;24(2):129–43. Available from: http://onlinelibrary.wiley.com.eresources.shef.ac.uk/doi/10.1046/j.1365-2214.1998.00052.x/epdf

13. Okike IO, Johnson AP, Henderson KL, Blackburn RM, Muller-Pebody B, Ladhani SN, et al. Incidence, etiology, and outcome of bacterial meningitis in infants aged. Clin Infect Dis [Internet]. 2014;59(10):e150-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24997051

14. Poelman R, Schölvinck EH, Borger R, Niesters HGM, Van Leer-Buter C. The emergence of enterovirus D68 in a Dutch University Medical Center and the necessity for routinely screening for respiratory viruses. J Clin Virol. 2015;62:1–5.

15. Hamilton MS, Jackson MA, Abel D. Clinical utility of polymerase chain reaction testing for enteroviral meningitis. Pediatr Infect Dis J [Internet]. 1999 Jun [cited 2014 Aug 27];18(6):533–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10391184

16. Ramers C, Billman G, Hartin M, Sm MTA, Sawyer MH. Impact of a Diagnostic Cerebrospinal Fluid on Patient Management. 2013;283(20):2680–5.

17. Modlin JF, Polk BF, Horton P, Etkind P, Crane E, Spiliotes A. Perinatal ECHOvirus Infection: Risk of Transmission during a Community Outbreak. N Engl J Med. 1981;

18. Yun KW, Choi EH, Cheon DS, Lee J, Choi CW, Hwang H, et al. Enteroviral meningitis without pleocytosis in children. Arch Dis Child [Internet]. 2012 Oct [cited 2014 Aug 19];97(10):874–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22814522

19. Sells CJ, Carpenter RL, Ray CG. Sequelae of central-nervous-system enterovirus infections. N Engl J Med [Internet]. 1975 Jul 3 [cited 2014 Aug 26];293(1):1–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1168853

20. Balasubramanian H, Wagh D, Rao S, Keil AD MJ. Developmental outcomes in cerebrospinal fluid proven enteroviral meningitis in neonates >32 weesk of gestation. J Paediatr Child Heal. 2016;53(3):327–32.

21. Farmer K, MacArthur BA, Clay MM. A follow-up study of 15 cases of neonatal meningoencephalitis due to Coxsackie virus B5. J Pediatr [Internet]. 1975 Oct [cited 2014 Aug 26];87(4):568–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/1159585

22. Bergman I, Painter MJ, Wald ER, Chiponis D, Holland AL, Taylor HG. Outcome in children with enteroviral meningitis during the first year of life. J Pediatr [Internet]. 1987 May [cited 2014 Aug 26];110(5):705–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2437277

23. Rorabaugh ML, Berlin LE, Heldrich F, Roberts K, Rosenberg LA, Doran T, et al. Aseptic meningitis in infants younger than 2 years of age: acute illness and neurologic complications. Pediatrics [Internet]. 1993 Aug [cited 2014 Aug 26];92(2):206–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8337018

24. Baker RC, Kummer AW, Schultz JR, Ho M, Gonzalez del Rey J. Neurodevelopmental outcome of infants with viral meningitis in the first three months of life. Clin Pediatr (Phila) [Internet]. 1996 Jun [cited 2014 Aug 26];35(6):295–301. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8782953

25. Ferreras Antolín L, Kadambari S, Braccio S, Tang JW, Xerry J, Allen DJ LSPSN. Increased detection of human parechovirus infection in infants in England during 2016: epidemiology and clinical characteristics. Arch Dis Child. 2018;

26. Piralla A, Furione M, Rovida F, Marchi A, Stronati M, Gerna G, et al. Human parechovirus infections in patients admitted to hospital in Northern Italy, 2008-2010. J Med Virol [Internet]. 2012;84(4):686–90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22337310

27. Harvala H, Calvert J, Van Nguyen D, Clasper L, Gadsby N, Molyneaux P, et al. Comparison of diagnostic clinical samples and environmental sampling for enterovirus and parechovirus surveillance in Scotland, 2010 to 2012. Eurosurveillance. 2014;19(15).

28. Tang JW, Holmes CW, Elsanousi FA, Patel A, Adam F, Speight R, Shenoy S, Bronnert D, Stiefel G, Sundaram P, Pande S, Sridhar A, Kairamkonda V BS. Cluster of human parechovirus infections as the predominant cause of sepsis in neonates and infants, Leicester, United Kingdom, 8 May to 2 August 2016. Eurosurveillance. 2016;21(34).

29. Britton PN, Dale RC, Nissen MD, Crawford N, Elliot E, Macartney K, et al. Parechovirus Encephalitis and Neurodevelopmental Outcomes. Pediatrics [Internet]. 2016 Jan 20 [cited 2016 Feb 18];137(2):1–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26791970

30. Verboon-Maciolek MA, Groenendaal F, Hahn CD, Hellmann J, Van Loon AM, Boivin G, et al. Human parechovirus causes encephalitis with white matter injury in neonates. Ann Neurol. 2008;64(3):266–73.

31. Kadambari S, Bukasa a, Okike I, Pebody R, Brown D, Gallimore C, et al. Enterovirus infections in england and wales, 2000-2011: the impact of increased molecular diagnostics. Clin Microbiol Infect [Internet]. 2014 Jul 4 [cited 2014 Jul 24]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/25039903

32. Kestenbaum LA, Ebberson J, Zorc JJ, Hodinka RL, Shah SS. Defining cerebrospinal fluid white blood cell count reference values in neonates and young infants. Pediatrics [Internet]. 2010;125(2):257–64. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3033868&tool=pmcentrez&rendertype=abstract

|  |  |
| --- | --- |
| **Parameter** | **Definition**  |
| Early-onset | 0-6 days |
| Late-onset | 7-89 days |
| Preterm | <37 weeks gestation |
| Term | ≥37 weeks |
| CSF pleocytosis | >20 white cells per mm3(32) |
| Features of circulatory shock included any combination of hypotension, mottled skin, capillary refill time >2 seconds, tachycardia >160 beats/min and/or reduced urinary output <2mls/kg/hr. |

**Table 1:** Definitions of demographic and clinical parameters

|  |  |
| --- | --- |
|  | **Age at diagnosis**  |
|  | **0-6 days** | **7 – 28 days** | **29 – 89 days** | **All cases** |
| **Virus:**EVHPeV | 64 (91)6 (9) | 207 (94)13 (6) | 372 (96)15 (4) | 643 (95)34 (5) |
| **Site of admission:**PICUHDUWardPAU | 29 (42)5 (7)35 (51)0 | 16 (7)15 (7)169 (74)29 (13) | 7 (2)12 (3)335 (86)34 (9) | 52 (8)32 (4)539 (79)63 (9) |
| **Clinical presentation:**FeverIrritabilityLethargyReduced feedingRespiratory distress | 49 (68)26 (36)33 (45)35 (49) 19 (26) | 186 (83)146 (65)88 (39)121 (54)32 (14) | 342 (90)277 (73)130 (34)211 (55)23 (6) | 577 (34)449 (26)251 (15)367 (21)74 (4) |
| **Laboratory findings:**WCCNeutrophilCRPCSF WCC | 10.3 (8.0 – 14.7)6.8 (4 – 10.7)14 (5 – 25)6 (2 – 32)  | 9.8 (3.9 – 20.8)4.6 (3.5 – 6.8)11 (4 – 22)8 (2 – 102) | 9.3 (7.2 – 12)4.1 (2.9 – 6)8 (3.9 – 16.8)26 (2 – 122) | 9.85.1119 |
| **Outcome at discharge:**RecoveredSequaleDied | 65 (97)2 (3)0 | 202 (98)3 (1)2 (1) | 340 (98)8 (2)0 | 607 (98)13 (2)2 (0) |
| **Serotype**Coxsackie B4Coxsackie B5Echovirus 7Echovirus 9Echovirus 11Echovirus 18Echovirus 25Echovirus 30 Enterovirus 71Untyped | 4 (10)1 (2)3 (7)9 (22)4 (10)4 (10)3 (7)1 (2)1 (2)5 (12) | 8 (6)11 (8)12 (9)18 (13)3 (2)13 (9)4 (3)7 (5)10 (7)33 (24) | 16 (6)20 (7)24 (9)48 (18)12 (4)26 (10)18 (7)9 (3)6 (2)55 (21) | 28 (7)32 (8)39 (10)75 (20)19 (5)43 (12)25 (6)17 (4)17 (4)93 (24) |

*Data are presented as numbers of cases (%)*

**Table 2:** Characteristics of infants aged <90 day with EV and HPeV meningitis in the United Kingdom and Ireland during July 2014 to July 2015 inclusive

EV= enterovirus; HPeV = Human parechovirus; PICU = Paediatric intensive Care Unit; HDU = High Dependency unit; PAU=Paediatric Assessment Unit; CSF = Cerebrospinal fluid; WCC = white cell count; CRP = C reactive protein

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Presenting features** | **Admission to Intensive Care**  | **Neuroimaging findings** | **Outcome at hospital discharge** | **Outcome at 12 months** |
| **EV deaths** |  |  |  |  |  |
| Born at term <1 week old EV11 infection | Afebrile, lethargic, reduced feeding; developed multi-organ failure and shock. CRP 6, CSF WCC clotted | Intubated & ventilated (13 d), inotropes (12 d); IV corticosteroids + IVIG  | Cranial ultrasound scan normal; echocardiogram – mitral valve regurgitation and valvulitis | Died after 2 weeks of massive pulmonary haemorrhage |  |
| Born at term 1 month EV (not typed) | Reduced feeding; circulatory collapse; rapid deterioration CRP 52; CSF WCC 0 | Intubated & ventilated (1 d), inotropes (1 d)  | Not performed | Died within 48 hours; EV isolated from heart and brain tissue at post mortem |  |
| **EV sequelae** |  |  |  |  |  |
| Premature (33-36 wks) 1 month old EV11 infection | Respiratory distress, apnoeaCRP 4.6, CSF WCC 0 | Intubated & ventilated (1 d), inotropes (2 d), haemofiltration (1d) | MRI: diffuse encephalitis and microcephaly. | Reduced tone trunk, increased tone in the limbs | Reduced vision, reduced truncal tone, increased tone in the limbs; seizures |
| Born at term<1 week oldCoxsackie B4 infection | Fever, irritability, respiratory distress, bulging fontanelle, cardiovascular shock CRP 45, CSF WCC 20 | Intubated & ventilated (35 d) ionotropic support; 1 dose IVIG | MRI: acute infarction, right anterior corona  | Poor ventricular function requiring medical treatment | Poor ventricular function, on captopril  |
| **HPeV sequelae** |  |  |  |  |  |
| Born at term1 week oldHPeV (not typed) | Irritability poor feeding, respiratory distress, signs of shockCRP 8, CSF WCC 2 | Not admitted  | Not performed  | Transaminitis (normal abdominal ultrasound) at discharge  | Well |
| **12 month follow-up** |  |  |  |  |  |
| Premature (28-32 wks)1 month oldEV (not typed) | Lethargy, reduced feeding, apnoea CRP 5, CSF WCC 13 | Intubated & ventilated (5 d), | MRI: severe cystic encephalomalacia, multiple fluid filled cysts in frontal, parietal & temporal lobes  | No clinical symptoms or signs | Seizures controlled on anti-epileptics |
| Born at term1 week oldEV (not typed) | Fever, irritability, rash, seizure; CRP 99; CSF WCC 90 | Not admitted  | Cranial ultrasound normal | Well at discharge  | Tonic clonic seizures; not on regular anticonvulsants |

**Table 3.** Death and Sequelae among infants aged <90 days with enterovirus (EV) and human parechovirus (HPeV) meningitis in the United Kingdom and Ireland during July 2014 to July 2015 inclusive. IVIG, intravenous immunoglobulin; CRP, c-reactive protein.mg/dl; CSF WCC, cerebrospinal fluid white cell count/per mm3;